ProNAi Therapeutics, Inc.
ProNAi is dedicated to commercializing a new class of therapies that target DNA to treat patients with cancer.
ProNAi Therapeutics is applying proprietary, nucleic acid-based DNA interference technology (DNAi®) to develop novel therapeutic approaches for proliferative diseases. The company was founded in 2004 by pharmaceutical scientists who have substantial experience in the area of nucleic acid research. The founders leveraged their experience to design a new class of therapies. ProNAi’s most advanced product, PNT2258, is currently in clinical trials.